32 results about "Amine oxidase inhibitors" patented technology

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A_2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT₂ antagonist or the like), and the like.

The invention relates to applications of liquidambar formosana hance fruit tannin monomer. The monomer comprises the components of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate. The invention relates to the application of the monomer in preparing a monoamine oxidase inhibitor. The invention is characterized in that the invention relates to the applications of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate in preparing medicines used for treating depression and Parkinson's disease.

The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual in which a vitamin B1, its derivative, its precursor or metabolite is administered to the individual. In addition, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, as well as a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.

The invention provides phenylidene phenyl peptide compounds, a medicinal composition using the phenylidene phenyl peptide compounds as active components, and application thereof as monoamine oxidase B(MAO-B) inhibitors and application thereof to preparation of medicines for treating Parkinson's disease (PD). Monoamine oxidase B (MAO-B) has been proved to be closely related to the pathogenesis ofthe Parkinson's disease (PD) and is a classic target for research and development of the medicines for treating the Parkinson's disease (PD). The invention provides application of the phenylidene phenyl peptide compounds to preparation of the monoamine oxidase B (MAO-B) inhibitors. In-vitro kinase activity experiments prove that the phenylidene phenyl peptide compounds have a significant monoamineoxidase B (MAO-B) inhibiting effect.

The invention provides a method for predicting a hemorrhagic disorder in a patient consisting determining amine oxidase and, particularly, VAP-1 in a sample from said patient. The invention also provides pharmaceutical compositions comprising an inhibitor of amine oxidase and an antithrombotic agent as well as the use of an inhibitor of amine oxidase for treatment of hemorrhagic disorders.

The invention relates to a compound having SSAO/VAP-1 inhibitor activity for use in the treatment of hyperalgesia and allodynia implicated in traumatic neuropathy or neurogenic inflammation. Accordingly, the invention relates to a compound having SSAO/VAP-1 inhibitor activity for use in the inhibition of pathological activation and dysfunctions of peptidergic sensory nerves caused by mechanical damage or chemical activation of peptidergic sensory nerves in neurogenic inflammation.

The invention discloses a preparation method and application of a monoamine oxidase A inhibitor. The preparation method comprises the steps: S1, Chinese prickly ash and an ethanol solution are placedin to a container, and an extract solution is obtained through heating reflux; S2, ethanol is removed after reduced-pressure concentration, and an aqueous solution is obtained; S3, the PH value is adjusted to be 2-3, and acid filtrate and precipitates are obtained through filtering and precipitation; S4, after the precipitates are dried, an extract of the precipitates are obtained; S5, the PH value of the acid filtrate is adjusted to be 9-10, and alkaline filtrate is obtained; S6, the alkaline filtrate is extracted through dichloromethane, dichloromethane extraction liquid is obtained, and after concentration and drying, a dichloromethane extract-phase extract is obtained; S7, the alkaline filtrate is extracted through n-butanol, n-butanol extraction liquid is obtained, and after concentration and drying, an n-butanol extract-phase extract is obtained; and S8, sulfuric acid is added into the alkaline filtrate to adjust the PH value to be neutral, and an extract of a mother solution isobtained. The monoamine oxidase A inhibitor can be applied to prevention and treatment of related diseases with the excessively-high monoamine oxidase A activity.

Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.

The invention relates to application of a Tibetan medicine duhat fruit tannin monomer, and in particular relates to application of a duhat fruit tannin monomer consisting of gallic acid, methyl gallate and 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one in preparing a monoamine oxidase inhibitor. The application is characterized in that gallic acid, methyl gallate and 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one are applied to preparation of medicines for treating depression and Parkinson disease.

The invention discloses applications of 1-tetralone compound in preparation of monoamine oxidase inhibitors. The structure of the compound is shown as a formula (I). Through enzyme activity test in vitro, the compound can have good inhibitory activity on monoamine oxidase A and B, so that reference and new inspiring ideas can be provided for the development of novel MAO inhibitors.